US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

20.26

+1.729.28%

Post-market: 20.260.00000.00%17:28 EDT

Volume:215.20K

Turnover:4.20M

Market Cap:558.02M

PE:-8.66

High:20.39

Open:18.54

Low:18.13

Close:18.54

Loading ...

Overview Company News Filings

Major Stock Sell-Off at Compass Therapeutics by Key Directors!

Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges

Promising Phase 2 Results and Technological Integration Justify Buy Rating for Alterity Therapeutics

Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating

Travere Therapeutics price target lowered to $30 from $32 at Scotiabank

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

MindBio Therapeutics Announces Strategic Financial Initiatives

Buy Rating for Unicycive Therapeutics: Competitive Advantages of Oxylanthanum Carbonate in Hyperphosphatemia Treatment

Promising Clinical Outcomes and Strategic Advances Boost Candel Therapeutics’ CAN-2409 Potential in Oncology

Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate

Argenica Therapeutics Says Final Patient Dosed in Phase Two Acute Ischaemic Stroke Drug Candidate Trial; Shares Rise 3%

MT Newswires Live

Gain Therapeutics Unveils New Parkinson’s Treatment Data

Arcturus Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial

MT Newswires Live

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m

Simply Wall St.

Tempest Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy

MT Newswires Live

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":20.26,"timestamp":1744401600000,"preClose":18.54,"halted":0,"volume":215197,"hourTrading":{"tag":"盘后","latestPrice":20.26,"preClose":20.26,"latestTime":"17:28 EDT","volume":4,"amount":81.46,"timestamp":1744406882488},"delay":0,"floatShares":11212266,"shares":27542874,"eps":-2.338654,"marketStatus":"Market Closed","change":1.72,"latestTime":"04-11 16:00:00 EDT","open":18.54,"high":20.39,"low":18.13,"amount":4201264.561769,"amplitude":0.121899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.338654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":18.54,"preHourTrading":{"tag":"盘前","latestPrice":18.01,"preClose":18.54,"latestTime":"04:59 EDT","volume":3,"amount":52.840005,"timestamp":1744361949934},"postHourTrading":{"tag":"盘后","latestPrice":20.26,"preClose":20.26,"latestTime":"17:28 EDT","volume":4,"amount":81.46,"timestamp":1744406882488},"volumeRatio":0.4607806401704022,"impliedVol":0.2737,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11212266,"roa":"-25.64%","roe":"-38.94%","lyrEps":-2.338654,"volumeRatio":0.4607806401704022,"shares":27542874,"dividePrice":0,"high":20.39,"amplitude":0.121899,"preClose":18.54,"low":18.13,"week52Low":14.42,"pbRate":"2.73","week52High":38.93,"institutionHeld":0,"latestPrice":20.26,"eps":-2.338654,"divideRate":0,"volume":215197,"delay":0,"ttmEps":-2.338654,"open":18.54,"prevYearClose":28.87,"prevWeekClose":21.18,"prevMonthClose":25.71,"prevQuarterClose":25.71,"fiveDayClose":21.18,"twentyDayClose":25.45,"sixtyDayClose":22.91},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526620021","title":"Major Stock Sell-Off at Compass Therapeutics by Key Directors!","url":"https://stock-news.laohu8.com/highlight/detail?id=2526620021","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526620021?lang=en_us&edition=fundamental","pubTime":"2025-04-12 10:02","pubTimestamp":1744423354,"startTime":"0","endTime":"0","summary":"New insider activity at Compass Therapeutics ( ($CMPX) ) has taken place on April 12, 2025. In a significant move, Director Carl Gordon and Directo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-stock-sell-off-at-compass-therapeutics-by-key-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-stock-sell-off-at-compass-therapeutics-by-key-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","CMPX"],"gpt_icon":0},{"id":"2526645262","title":"Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2526645262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526645262?lang=en_us&edition=fundamental","pubTime":"2025-04-12 04:15","pubTimestamp":1744402522,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their neutral stance on ADAP stock, giving a Hold rating on March 25. Soumit Roy has given his Hold ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adaptimmune-therapeutics-hold-rating-amid-financial-uncertainties-and-strategic-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adaptimmune-therapeutics-hold-rating-amid-financial-uncertainties-and-strategic-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2526061285","title":"Promising Phase 2 Results and Technological Integration Justify Buy Rating for Alterity Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2526061285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526061285?lang=en_us&edition=fundamental","pubTime":"2025-04-12 02:25","pubTimestamp":1744395920,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Alterity Therapeutics (ATHE – Research Report), retaining the price target of $12....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-phase-2-results-and-technological-integration-justify-buy-rating-for-alterity-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-phase-2-results-and-technological-integration-justify-buy-rating-for-alterity-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2526184736","title":"Promising Developments in Gain Therapeutics’ Parkinson’s Treatment Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2526184736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526184736?lang=en_us&edition=fundamental","pubTime":"2025-04-12 00:35","pubTimestamp":1744389310,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Gain Therapeutics (GANX – Research Report), with a price...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-gain-therapeutics-parkinsons-treatment-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-gain-therapeutics-parkinsons-treatment-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","GANX"],"gpt_icon":0},{"id":"2526069643","title":"Travere Therapeutics price target lowered to $30 from $32 at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2526069643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526069643?lang=en_us&edition=fundamental","pubTime":"2025-04-11 22:20","pubTimestamp":1744381222,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-lowered-to-30-from-32-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-lowered-to-30-from-32-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2526621566","title":"Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2526621566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526621566?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:15","pubTimestamp":1744377300,"startTime":"0","endTime":"0","summary":"ATLANTA, April  11, 2025  (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/11/3060104/0/en/Dogwood-Therapeutics-Inc-Receives-Nasdaq-Confirmation-of-Compliance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","USJW.SI","BK4139","TSYW.SI","LU2210150020.SGD","NVIW.SI","IE00BGHQF748.EUR","USAW.SI","SQQQ","NDAQ","QID","BK4112","BK4585","IE00B3QW5Z07.USD","TQQQ","IE00B64PRP62.GBP","QLD","MNQmain","LU2210149790.SGD","NQmain","LENZ","IE00BKPKM429.USD","PSQ","BK4007","BK4588",".IXIC"],"gpt_icon":1},{"id":"2526664225","title":"MindBio Therapeutics Announces Strategic Financial Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2526664225","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526664225?lang=en_us&edition=fundamental","pubTime":"2025-04-11 21:09","pubTimestamp":1744376952,"startTime":"0","endTime":"0","summary":"An update from Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) is now available. MindBio Therapeutics Corp. has announced a private placement and debt s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mindbio-therapeutics-announces-strategic-financial-initiatives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mindbio-therapeutics-announces-strategic-financial-initiatives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2526517706","title":"Buy Rating for Unicycive Therapeutics: Competitive Advantages of Oxylanthanum Carbonate in Hyperphosphatemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526517706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526517706?lang=en_us&edition=fundamental","pubTime":"2025-04-11 18:36","pubTimestamp":1744367814,"startTime":"0","endTime":"0","summary":"Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Unicycive Therapeutics (UNCY – Research Report). The associated price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-unicycive-therapeutics-competitive-advantages-of-oxylanthanum-carbonate-in-hyperphosphatemia-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-unicycive-therapeutics-competitive-advantages-of-oxylanthanum-carbonate-in-hyperphosphatemia-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","LENZ"],"gpt_icon":0},{"id":"2526512486","title":"Promising Clinical Outcomes and Strategic Advances Boost Candel Therapeutics’ CAN-2409 Potential in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2526512486","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526512486?lang=en_us&edition=fundamental","pubTime":"2025-04-11 18:35","pubTimestamp":1744367732,"startTime":"0","endTime":"0","summary":"Analyst Vernon Bernardino of H.C. Wainwright reiterated a Buy rating on Candel Therapeutics (CADL – Research Report), retaining the price target of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-outcomes-and-strategic-advances-boost-candel-therapeutics-can-2409-potential-in-oncology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-outcomes-and-strategic-advances-boost-candel-therapeutics-can-2409-potential-in-oncology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4595","BK4139","LENZ","BK4539","BK4526","BK4170","CADL","BK4600"],"gpt_icon":0},{"id":"2526636771","title":"Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate","url":"https://stock-news.laohu8.com/highlight/detail?id=2526636771","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526636771?lang=en_us&edition=fundamental","pubTime":"2025-04-11 16:35","pubTimestamp":1744360526,"startTime":"0","endTime":"0","summary":"Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report) yesterday and set a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/unicycive-therapeutics-buy-rating-on-imminent-fda-approval-and-market-potential-of-oxylanthanum-carbonate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/unicycive-therapeutics-buy-rating-on-imminent-fda-approval-and-market-potential-of-oxylanthanum-carbonate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","LENZ"],"gpt_icon":0},{"id":"2526570829","title":"Argenica Therapeutics Says Final Patient Dosed in Phase Two Acute Ischaemic Stroke Drug Candidate Trial; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526570829","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526570829?lang=en_us&edition=fundamental","pubTime":"2025-04-11 11:07","pubTimestamp":1744340874,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","AGN.AU","BK4139","BK7096"],"gpt_icon":0},{"id":"2526997528","title":"Gain Therapeutics Unveils New Parkinson’s Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2526997528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526997528?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:18","pubTimestamp":1744319935,"startTime":"0","endTime":"0","summary":"Gain Therapeutics ( ($GANX) ) has issued an update. On April 10, 2025, Gain Therapeutics announced the presentation of new preclinical data and the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gain-therapeutics-unveils-new-parkinsons-treatment-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gain-therapeutics-unveils-new-parkinsons-treatment-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GANX","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2526511352","title":"Arcturus Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526511352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526511352?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:58","pubTimestamp":1744304280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 12:58 ET (16:58 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","LENZ"],"gpt_icon":0},{"id":"2526559703","title":"Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2526559703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526559703?lang=en_us&edition=fundamental","pubTime":"2025-04-10 23:35","pubTimestamp":1744299313,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of $60.00. E...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/arcturus-therapeutics-buy-rating-backed-by-promising-vaccine-development-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/arcturus-therapeutics-buy-rating-backed-by-promising-vaccine-development-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2526659586","title":"Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526659586","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526659586?lang=en_us&edition=fundamental","pubTime":"2025-04-10 22:13","pubTimestamp":1744294382,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics  said Thursday that the external Safety Review Committee recommended that the company's phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, in advanced cancer should proceed to cohort 6, 30mg capsules, without any modification.The recommendation was based on the review of the safety data from three patients from cohort 5 and the absence of any dose limiting toxicities, or DLT, the biotechnology company said.During the DLT period, no rash was observed to date in any of the first 19 patients in either capsule or tablet formulation of PAS-004. Rash is a common adverse event that is observed at low doses with competitor MEK inhibitors, Pasithea said.Shares were up 50% in early Thursday trading.Price: 1.62, Change: +0.54, Percent Change: +50.00","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLZ.SI","BK4157","BK6522","IE00B19Z4B17.USD","BK6088","IE00B7SZL793.SGD","LENZ","IE00B66KJ199.SGD","AEIS","KTTA","BK4007","BK4139","IE0031619046.USD"],"gpt_icon":0},{"id":"2526674205","title":"Travere Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2526674205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526674205?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:41","pubTimestamp":1744292460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 09:41 ET (13:41 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","LENZ"],"gpt_icon":0},{"id":"2526672405","title":"Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m","url":"https://stock-news.laohu8.com/highlight/detail?id=2526672405","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526672405?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:03","pubTimestamp":1744290187,"startTime":"0","endTime":"0","summary":"Insiders who acquired US$1.06m worth of Dyne Therapeutics, Inc.'s  stock at an average price of US$33.04 in the past 12 months may be dismayed by the recent 24% price decline. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$241.6k which is not ideal.While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.Dyne Therapeutics Insider Transactions Over The Last Year. The fact that there have been no Dyne Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. The transactions are fine but it'd be more encouraging if Dyne Therapeutics insiders bought more share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-purchases-worth-us-1-130307614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DYN","BK4588","LENZ","BK4505","BK4007","BK4585","BK4139"],"gpt_icon":0},{"id":"2526565220","title":"Tempest Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2526565220","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526565220?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:23","pubTimestamp":1744287780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TPST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 08:23 ET (12:23 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TPST"],"gpt_icon":0},{"id":"2526653735","title":"HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526653735","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526653735?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:14","pubTimestamp":1744287261,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TPST","LENZ"],"gpt_icon":0},{"id":"2526563906","title":"Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563906","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563906?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening DiseasesANN ARBOR, Mich., April  10, 2025  (GLOBE NEWSWIRE) -- Esperion (NA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/10/3059169/0/en/Esperion-to-Host-R-D-Day-to-Highlight-Cardiometabolic-Pipeline-Innovation-and-Next-Generation-Therapeutics-on-April-24-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4181","BK4585","LENZ","ESPR","BK4139","HST","BK4588","BK4218"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":1,"totalSize":255,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-04-11","current":-10.2603,"percent":0.430328,"low":-16.900596,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"high":-5.069183,"avg":-9.953888,"sd":3.205285,"marketCap":510644883},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883}],"updateTime":1744553246221}}}